UroGen Pharma to Report First Quarter 2019 Financial Results on Thursday, May 9, 2019
Last urogen pharma ltd earnings: 3/2 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations: investors.urogen.com
Conference Call and Webcast Scheduled for 8:30 AM ET NEW YORK--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq:URGN) today announced that it will report first quarter 2019 financial results on Thursday, May 9, 2019, prior to the open of the market. The announcement will be followed by a live audio webcast and conference call at 8:30AM Eastern Time. Audio Webcast The webcast will be made available on the Investors section of the Company’s website at http://investors.urogen.com. Following the live audio webcast, a replay will be available on the Company's website for approximately two weeks. Dial-In Information Live (U.S. / Canada): 1 (888) 771-4371Live (International): 1 (847) 585-4405Confirmation number: 48486174 About UroGen Pharma Ltd. UroGen Pharma Ltd. (Nasdaq:URGN) is a clinical-stage biopharmaceutical company developing advanced non-surgical tr
[Read more]
| Impact snapshot | Event time: | URGN | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last price | ||
| VWAP | ||
|
High:
|
Max up |
High:
|
|
Low:
|
Max down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event Day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance Since Event
Time and Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
SIGN UP TODAY
Opt-in for
URGN alerts
URGN alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
URGN alerts
High impacting UroGen Pharma Ltd news events
Weekly update
A roundup of the hottest topics
URGN
News
- UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- UroGen Pharma Announces Podium Presentation of Final Jelmyto® Data From Pivotal OLYMPUS Trial at the Annual Meeting of the Society of Urologic OncologyBusiness Wire
- Complete and Durable Responses Observed in OPTIMA II Phase 2b Final Results for UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder CancerBusiness Wire
- Centers for Medicare & Medicaid Services (CMS) Issues Permanent J-Code for UroGen’s Jelmyto® Effective January 1, 2021Business Wire
- UroGen Pharma Ltd. (<a href="https://www.marketbeat.com/stocks/NASDAQ/URGN/price-target/">NASDAQ: URGN</a>) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $48.00 to $40.00.MarketBeat
- More
URGN
SEC Filings
- 12/4/20 - Form 4
- 12/3/20 - Form 8-K
- 11/17/20 - Form 8-K
- URGN's page on the SEC website
- More